Compare PLAB & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | FTRE |
|---|---|---|
| Founded | 1969 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1995 | 2023 |
| Metric | PLAB | FTRE |
|---|---|---|
| Price | $27.57 | $20.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $41.33 | $23.63 |
| AVG Volume (30 Days) | 782.1K | ★ 2.0M |
| Earning Date | 12-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | $535,276,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $2.20 | N/A |
| Revenue Next Year | $2.81 | $3.21 |
| P/E Ratio | $15.81 | ★ N/A |
| Revenue Growth | ★ 18.77 | 1.00 |
| 52 Week Low | $20.05 | $8.55 |
| 52 Week High | $56.00 | $26.16 |
| Indicator | PLAB | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 43.94 |
| Support Level | $24.92 | $19.36 |
| Resistance Level | $29.89 | $21.25 |
| Average True Range (ATR) | 1.22 | 1.48 |
| MACD | 0.05 | -0.35 |
| Stochastic Oscillator | 50.31 | 17.94 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.